Search research articles
Contact Us
Filters
Showing results (801-810 of 831) with videos related to
Page
of 84
Sort By:
Journal of Medicinal Chemistry
|
June 14, 2024
Correction to "Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead"
N G R Dayan Elshan, Karen C Wolff, Laura Riva, et al.
Nature Communications
|
June 4, 2021
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Malina A Bakowski, Nathan Beutler, Karen C Wolff, et al.
Clinical Breast Cancer
|
September 28, 2019
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Rachel A Freedman, Rebecca S Gelman, Nathalie Y R Agar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 10, 2009
Breast cancer. Clinical practice guidelines in oncology
Robert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 21, 2010
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al.
Breast Cancer Research and Treatment
|
May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2016
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
Heather A Parsons, Julia A Beaver, Ashley Cimino-Mathews, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
Cell Reports
|
November 6, 2024
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
Nian E Zhou, Su Tang, Xuelin Bian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart, Eileen Holmes, José Baselga, et al.
Page
of 84
Search research articles
Search
Showing results (801-810 of 831) with videos related to
Sort By:
Page
of 84
Journal of Medicinal Chemistry
|
June 14, 2024
Correction to "Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead"
N G R Dayan Elshan, Karen C Wolff, Laura Riva, et al.
Nature Communications
|
June 4, 2021
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Malina A Bakowski, Nathan Beutler, Karen C Wolff, et al.
Clinical Breast Cancer
|
September 28, 2019
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Rachel A Freedman, Rebecca S Gelman, Nathalie Y R Agar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 10, 2009
Breast cancer. Clinical practice guidelines in oncology
Robert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 21, 2010
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al.
Breast Cancer Research and Treatment
|
May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2016
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
Heather A Parsons, Julia A Beaver, Ashley Cimino-Mathews, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
Cell Reports
|
November 6, 2024
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
Nian E Zhou, Su Tang, Xuelin Bian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart, Eileen Holmes, José Baselga, et al.
Page
of 84